Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy

NCT02643251 · View on ClinicalTrials.gov ↗

Study Summary

The study will include three (3) phases: Screening Phase, Treatment Phase, and Follow-up Phase. Subjects who qualify to participate will apply study drug to their feet three times daily and will record their daily pain scores using an interactive voice response system (IVRS) during the Treatment Phase for 12 weeks. Approximately 100 adult subjects will be randomized to receive Clonidine Gel or Clonidine Gel Comparator.

Interventions

  • DRUG Clonidine Hydrochloride Topical Gel, 0.1%
  • DRUG Clonidine Hydrochloride Gel Comparator

Study Locations (20)

California

  • — Anaheim
  • — Norco
  • — Sacramento
  • — Santa Monica
  • — Tustin

Florida

  • — Fort Myers
  • — Ocala
  • — Orlando
  • — Tampa
  • — West Palm Beach

Arizona

  • — Glendale
  • — Phoenix
  • — Phoenix

Illinois

  • — Belleville
  • — Blue Island
  • — Chicago

Idaho

  • — Blackfoot
  • — Boise

Missouri

  • — Hazelwood

Ohio

  • — Cleveland

Trial Details

FieldValue
Enrollment Target 138 participants
Start Date 2015-12
Est. Completion 2016-11
Phase Phase 2

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02643251

The ClinicalTrials.gov registry entry for NCT02643251 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioDelivery Sciences International, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Neuropathy appearing as the primary indexed condition, and to 2 interventions — of which Clonidine Hydrochloride Topical Gel, 0.1% is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02643251 reports 20 study locations spanning 7 distinct geographic areas — top geographies include California, Florida, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02643251 about?

NCT02643251 is a clinical study titled "The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy". The study will include three (3) phases: Screening Phase, Treatment Phase, and Follow-up Phase. Subjects who qualify to participate will apply study drug to their feet three times daily and will record their daily pain scores using an interactive voice response system (IVRS) during the Treatment Pha...

What is the current status of trial NCT02643251?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 138 participants. The study started on 2015-12. Estimated completion is 2016-11.

What conditions does trial NCT02643251 study?

This clinical trial studies the following conditions: Neuropathy, Diabetic Neuropathy, Painful Diabetic Neuropathy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02643251?

The interventions under investigation include: Clonidine Hydrochloride Topical Gel, 0.1% (DRUG), Clonidine Hydrochloride Gel Comparator (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02643251?

This trial is sponsored by BioDelivery Sciences International, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02643251 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial